Market Newsdesk

MISSISSAUGA, ON, Jan. 29, 2021 /CNW/ – Bird Construction Inc. (TSX: BDT) announced today that it will release its financial results for the quarter ended December 31, 2020 after market close on Tuesday, March 9, 2021, and will host a conference call and webcast to discuss the results on Wednesday, March 10, 2021 at 10:00 a.m. (ET).

Analysts and institutional investors are invited to access the conference call by dialing 1-855-328-1925 at least 10 minutes prior to the start.

A live webcast will be held at http://services.choruscall.ca/links/bird20210310.html. Participants should join at least 10 minutes prior to the start to register and install any necessary software. The accompanying presentation of the fourth quarter and fiscal 2020 financial results will be available after market close on Tuesday, March 9, 2021 at https://www.bird.ca/investors.  

Related financial documents will be posted at https://www.bird.ca/investors.

The Toronto Stock Exchange does not accept responsibility for the adequacy or accuracy of this release.

For further information contact:

T.L. McKibbon, President & CEO or

W.R. Gingrich, CFO

Bird Construction Inc.

5700 Explorer Drive, Suite 400


Mississauga, ON L4W 0C6

Phone: (905) 602-4122 

[email protected]

About Bird Construction

Bird (TSX:BDT) is a leading Canadian construction company operating from coast-to-coast and servicing all of Canada’s major markets. Bird provides a comprehensive range of construction services from new construction for industrial, commercial, and institutional markets; to industrial maintenance, repair and operations services, heavy civil construction, and contract surface mining; as well as vertical infrastructure including, electrical, mechanical, and specialty trades. For over 100 years, Bird has been a people-focused company with an unwavering commitment to safety and a high level of service that provides long-term value for all stakeholders. www.bird.ca 

SOURCE Bird Construction Inc.

SOUTH SAN FRANCISCO, Calif., Jan. 29, 2021 /PRNewswire/ — Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced it has been awarded $16.5 million by the U.S. Department of Defense’s (DOD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) to support Rigel’s ongoing Phase 3 clinical trial to evaluate the safety and efficacy of fostamatinib in hospitalized COVID-19 patients. Fostamatinib is marketed in the U.S. as TAVALISSE^® (fostamatinib disodium hexahydrate) tablets, and is approved in the U.S., Europe, and Canada as a treatment for adult chronic immune thrombocytopenia (ITP).

“We are grateful to receive this funding from the DOD and for their demonstrated commitment towards finding safe and effective treatments for COVID-19 patients,” said Raul Rodriguez, Rigel’s president and CEO. “These additional resources will contribute significantly to the advancement of our Phase 3 trial. Data from this trial, coupled with findings from the NIH-sponsored Phase 2 trial, which is anticipated to report topline results in April 2021, could potentially facilitate an EUA filing for a much needed therapy for hospitalized COVID-19 patients in the U.S.”

“The DOD is pleased to support this effort, since repurposing an existing FDA-approved drug product for potential application as a COVID-19 treatment saves time and cost, enabling a much more rapid response to the pandemic,” said Dr. Jason Roos, the Joint Program Executive Officer for Chemical, Biological, Radiological and Nuclear Defense. “This investment should speed up identification of safe and effective treatments for this formidable pandemic.”

The Phase 3 clinical trial will evaluate the safety and efficacy of fostamatinib in hospitalized COVID-19 patients without respiratory failure that have certain high-risk prognostic factors. This multi-center, double-blind, placebo-controlled, adaptive design study is expected to enroll over 300 evaluable patients that will be randomly assigned to either fostamatinib plus standard of care (SOC) or matched placebo plus SOC (1:1). Treatment will be administered orally twice daily for 14 days. There will be a follow-up period to day 60. The primary endpoint of this study is the proportion of subjects who progress to severe/critical disease within 29 days.

About COVID-19 & SYK Inhibition

COVID-19 is the infectious disease caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2).  SARS-CoV-2 primarily infects the upper and lower respiratory tract and can lead to acute respiratory distress syndrome (ARDS). Additionally, some patients develop other organ dysfunction including myocardial injury, acute kidney injury, shock resulting in endothelial dysfunction and subsequently micro and macrovascular thrombosis.¹ Much of the underlying pathology of SARS-CoV-2 is thought to be secondary to a hyperinflammatory immune response associated with increased risk of thrombosis.²

SYK is involved in the intracellular signaling pathways of many different immune cells. Therefore, SYK inhibition may improve outcomes in patients with COVID-19 via inhibition of key Fc gamma receptor (FcγR) and c-type lectin receptor (CLR) mediated drivers of pathology, such as inflammatory cytokine release by monocytes and macrophages, production of neutrophil extracellular traps (NETs) by neutrophils, and platelet aggregation.^3,4,5 Furthermore, SYK inhibition in neutrophils and platelets may lead to decreased thromboinflammation, alleviating organ dysfunction in critically ill patients with COVID-19.

About TAVALISSE


Indication
TAVALISSE^® (fostamatinib disodium hexahydrate) tablets is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.

Important Safety Information

Warnings and Precautions

• Hypertension can occur with TAVALISSE treatment. Patients with pre-existing hypertension may be more susceptible to the hypertensive effects. Monitor blood pressure every 2 weeks until stable, then monthly, and adjust or initiate antihypertensive therapy for blood pressure control maintenance during therapy. If increased blood pressure persists, TAVALISSE interruption, reduction, or discontinuation may be required.
• Elevated liver function tests (LFTs), mainly ALT and AST, can occur with TAVALISSE. Monitor LFTs monthly during treatment. If ALT or AST increase to >3 x upper limit of normal, manage hepatotoxicity using TAVALISSE interruption, reduction, or discontinuation.
• Diarrhea occurred in 31% of patients and severe diarrhea occurred in 1% of patients treated with TAVALISSE. Monitor patients for the development of diarrhea and manage using supportive care measures early after the onset of symptoms. If diarrhea becomes severe (≥Grade 3), interrupt, reduce dose or discontinue TAVALISSE.
• Neutropenia occurred in 6% of patients treated with TAVALISSE; febrile neutropenia occurred in 1% of patients. Monitor the ANC monthly and for infection during treatment. Manage toxicity with TAVALISSE interruption, reduction, or discontinuation.
• TAVALISSE can cause fetal harm when administered to pregnant women. Advise pregnant women the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment and for at least 1 month after the last dose. Verify pregnancy status prior to initiating TAVALISSE. It is unknown if TAVALISSE or its metabolite is present in human milk. Because of the potential for serious adverse reactions in a breastfed child, advise a lactating woman not to breastfeed during TAVALISSE treatment and for at least 1 month after the last dose.

Drug Interactions

• Concomitant use of TAVALISSE with strong CYP3A4 inhibitors increases exposure to the major active metabolite of TAVALISSE (R406), which may increase the risk of adverse reactions. Monitor for toxicities that may require a reduction in TAVALISSE dose.
• It is not recommended to use TAVALISSE with strong CYP3A4 inducers, as concomitant use reduces exposure to R406.
• Concomitant use of TAVALISSE may increase concentrations of some CYP3A4 substrate drugs and may require a dose reduction of the CYP3A4 substrate drug.
• Concomitant use of TAVALISSE may increase concentrations of BCRP substrate drugs (eg, rosuvastatin) and P-Glycoprotein (P-gp) substrate drugs (eg, digoxin), which may require a dose reduction of the BCRP and P-gp substrate drug.

Adverse Reactions

• Serious adverse drug reactions in the ITP double-blind studies were febrile neutropenia, diarrhea, pneumonia, and hypertensive crisis, which occurred in 1% of TAVALISSE patients. In addition, severe adverse reactions occurred including dyspnea and hypertension (both 2%), neutropenia, arthralgia, chest pain, diarrhea, dizziness, nephrolithiasis, pain in extremity, toothache, syncope, and hypoxia (all 1%).
• Common adverse reactions (≥5% and more common than placebo) from FIT-1 and FIT-2 included: diarrhea, hypertension, nausea, dizziness, ALT and AST increased, respiratory infection, rash, abdominal pain, fatigue, chest pain, and neutropenia.

Please see www.TAVALISSE.com for full Prescribing Information.

To report side effects of prescription drugs to the FDA, visit www.fda.gov/medwatch or call 1-800-FDA-1088 (800-332-1088).

TAVALISSE and TAVLESSE are registered trademarks of Rigel Pharmaceuticals, Inc.

About Rigel (www.rigel.com)

Rigel Pharmaceuticals, Inc., is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with hematologic disorders, cancer and rare immune diseases. Rigel’s pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company’s first FDA approved product is TAVALISSE^® (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The product is also commercially available in Europe (TAVLESSE) and Canada (TAVALISSE) for the treatment of chronic immune thrombocytopenia in adult patients.

Fostamatinib⁶ is currently being studied in a Phase 3 trial for the treatment of warm autoimmune hemolytic anemia (wAIHA); an NIH/NHLBI-sponsored Phase 2 trial for the treatment of hospitalized COVID-19 patients, in collaboration with Inova Health System; and a Phase 2 trial for the treatment of COVID-19 being conducted by Imperial College London. Additionally, has Rigel launched a Phase 3 clinical trial of fostamatinib for the treatment of hospitalized COVID-19 patients.

Rigel’s other clinical programs include an ongoing Phase 1 study of R835⁶, a proprietary molecule from its interleukin receptor-associated kinase (IRAK) inhibitor program, and a recently completed Phase 1 study of R552⁶, a proprietary molecule from its receptor-interacting serine/threonine-protein kinase (RIPK) inhibitor program. In addition, Rigel has product candidates in clinical development with partners AstraZeneca, BerGenBio ASA, and Daiichi Sankyo.

1. Berlin DA, Gulick RM, Martinez FJ. Severe Covid-19. N Engl J Med 2020
2. Becker RC. COVID-19 Update: COVID-19 associated coagulopathy. Journal of Thrombosis and Thrombolysis May 15, 2020. DOI: https://doi.org/10.1007/s11239-020-02134-3 
3. Hoepel W. et al. Anti-SARS-CoV-2 IgG from severely ill COVID-19 patients promotes macrophage hyper-inflammatory responses. bioRxiv July 13, 2020. DOI: https://doi.org/10.1101/2020.07.13.190140 
4. Sung P-S and Hsieh S-L (2019) CLEC2 and CLEC5A: Pathogenic Host Factors in Acute Viral Infections. Front. Immunol. 10:2867. DOI: https://doi.org/10.3389/fimmu.2019.02867 
5. Behnen M. Immobilized Immune Complexes Induce Neutrophil Extracellular Trap Release by Human Neutrophil Granulocytes via Fcγ RIIIB and Mac-1. The Journal of Immunology July 2014. DOI: https://doi.org/10.4049/jimmunol.1400478 
6. The product for this use or indication is investigational and has not been proven safe or effective by any regulatory authority.

Forward Looking Statements

This release contains forward-looking statements relating to, among other things, Rigel’s ability to receive payments under the DoD agreement, expected timing of the results of the NIH-sponsored Phase 2 trial and the potential for Rigel’s Phase 3 study to facilitate a filing for an EUA. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as “potential,” “may,” “expects” and similar expressions are intended to identify these forward-looking statements. These forward-looking statements are based on Rigel’s current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties associated with the commercialization and marketing of TAVALISSE; risks that the FDA, EMA or other regulatory authorities may make adverse decisions regarding fostamatinib; risks that TAVALISSE clinical trials may not be predictive of real-world results or of results in subsequent clinical trials; risks that TAVALISSE may have unintended side effects, adverse reactions or incidents of misuses; the availability of resources to develop Rigel’s product candidates; market competition; as well as other risks detailed from time to time in Rigel’s reports filed with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2019 and Quarterly Report on Form 10-Q for the quarter ended September 30, 2020. In addition, the COVID-19 pandemic may result in further delays in Rigel’s studies, trials and sales, or impact Rigel’s ability to obtain supply of TAVALISSE. Rigel does not undertake any obligation to update forward-looking statements and expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein.

Rigel Investor Contact: 
Phone: 650.624.1232
Email: [email protected]

Rigel Media Contact:
Phone: 315-409-9783
Email: [email protected]

 

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/rigel-awarded-16-5-million-from-us-department-of-defense-for-phase-3-clinical-trial-of-fostamatinib-in-covid-19-patients-301218290.html

SOURCE Rigel Pharmaceuticals, Inc.

INDIANAPOLIS, Jan. 29, 2021 /PRNewswire/ — Indianapolis Power & Light Company, a subsidiary of the AES Corporation (NYSE: AES), today announced additions to its senior leadership and government affairs teams. The expanded teams have new capabilities for IPL to innovate to serve its customers’ evolving needs.

Brandi Davis-Handy
 will join IPL in a newly created role, chief public relations officer, US Utilities, and will lead the communications and community efforts for AES in Indiana and Ohio. Davis-Handy has two decades of journalism, corporate communications and marketing experience. She has held leadership roles in the private, public and non-profit sectors, including positions at Project Lead the Way, OneAmerica, and the 500 Festival. She previously led communications for IPL and the AES US Strategic Business Unit (SBU) for five years. Davis-Handy graduated from Hampton University, was recognized as a Center for Leadership Development Minority Achiever and was named a Breakthrough Woman in Leadership Development by the National Coalition of 100 Black Women in 2018.

Aaron Cooper
 will assume the newly created role of chief commercial officer, US Utilities, covering commercial activities for AES in Indiana and Ohio. Cooper has more than 30 years of utility experience with Dayton Power & Light and AES. For more than a decade, he served as the director of fuel supply, where he supported AES-owned solid fuel generating stations in the US with fuel planning and procurement, logistics and contract administration. Cooper also has experience with Dayton Power & Light across a number of management functions, including customer accounts, operations, regulatory, commercial activities. Cooper graduated from Miami University in Ohio.

Fred Mills
, external affairs director, will retire this month after nearly two decades at IPL. Mills has served as a key leader in government and stakeholder roles, where he interfaced with federal, state and local elected officials. Mills also represented IPL on the Indiana Energy Association’s Government Relations Committee and numerous other boards. Most recently, Fred served as the company’s lead on the Indiana General Assembly’s 21st Century Energy Task Force where he helped shape the context for future energy policy discussions throughout Indiana.

“Fred has played an important role for IPL, representing the company with numerous stakeholders and working to advance the economic development goals of Indianapolis,” said Kristina Lund, IPL president and CEO. “In addition, Fred’s impact on AES extends beyond Indiana. Fred actively supported AES’ development of our businesses in Vietnam and Bulgaria. We are grateful for Fred’s leadership and many contributions over the years, and we wish him well in his retirement.”

Tom Raga
 will lead AES US Utilities’ government affairs teams across Indiana and Ohio. Raga has extensive public policy experience including service in local elected office and as a member of the Ohio House of Representatives. Since joining Dayton Power & Light in 2010, Raga has held management roles overseeing federal and state government relations, transmission resource planning, communications, strategic accounts, safety, environmental services, and corporate social responsibility. During the COVID-19 pandemic, Raga has spearheaded customer care efforts in both Indiana and Ohio to ensure customers had access to extended payment plans and other support.

Courtney Arango
has been named IPL’s government affairs director. Most recently, Arango has served as the company’s external affairs manager and spokeswoman. Arango has extensive experience in media, communications and policy. Previously, she was communications director in Governor Holcomb’s office, and she directed communications for the Indiana Department of Environmental Management (IDEM). Courtney has also served in communications roles for the Indiana Senate Majority Caucus and the State Lottery Commission of Indiana.                        

“IPL has a strong and dedicated leadership team, with many individuals who have served Indianapolis in important functions over the years,” said Lund. “We are pleased to add some additional capabilities to our team, as this is an important moment for us to innovate to better serve our customers and communities.”

About Indianapolis Power & Light Company and AES
Indianapolis Power & Light Company (IPL), an AES Company, provides retail electric service to more than 490,000 residential, commercial and industrial customers in Indianapolis, as well as portions of other Central Indiana communities surrounding Marion County. During its long history, IPL has supplied its customers with some of the lowest-cost, most reliable power in the country. For more information about the company, please visit IPLpower.com or connect at twitter.com/IPLpower,  facebook.com/IPLpower or linkedin.com/company/IPLpower.

The AES Corporation (NYSE: AES) is a Fortune 500 global energy company accelerating the future of energy. Together with our many stakeholders, we’re improving lives by delivering the greener, smarter energy solutions the world needs. Our diverse workforce is committed to continuous innovation and operational excellence, while partnering with our customers on their strategic energy transitions and continuing to meet their energy needs today. For more information, visit www.aes.com.

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/ipl-announces-expanded-senior-leadership-and-government-affairs-teams-301218284.html

SOURCE The AES Corporation